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genitors cells has emerged as a new therapeutic approach for
Wiskott-Aldrich syndrome (WAS), a primary immunodefi-
ciency with microthrombocytopenia and abnormal lymphoid
and myeloid functions. Despite the clinical benefits obtained
in ongoing clinical trials, platelet restoration is suboptimal.
The incomplete restoration of platelets in these patients can
be explained either by a low number of corrected cells or by
insufficient or inadequate WASP expression during megakar-
yocyte differentiation and/or in platelets. We therefore used
in vitro models to study the endogenous WASP expression
pattern during megakaryocytic differentiation and compared
it with the expression profiles achieved by different therapeutic
lentiviral vectors (LVs) driving WAS cDNA through different
regions of the WAS promoter. Our data showed that all WAS
promoter-driven LVs mimic very closely the endogenous
WAS expression kinetic duringmegakaryocytic differentiation.
However, LVs harboring the full-length (1.6-kb) WAS-prox-
imal promoter (WW1.6) or a combination of theWAS alterna-
tive and proximal promoters (named AW) had the best
behavior. Finally, all WAS-driven LVs restored the WAS
knockout (WASKO) mice phenotype and functional defects
of hematopoietic stem and progenitor cells (HSPCs) from a
WAS patient with similar efficiency. In summary, our data
back up the use of WW1.6 and AW LVs as physiological gene
transfer tools for WAS therapy.Received 6 May 2020; accepted 11 September 2020;
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Wiskott-Aldrich syndrome (WAS) is an X-linked rare primary im-
munodeficiency (incidence of 1 in 105 to 1 in 106 cases per live birth)
(OMIM: 301000) and makes up approximately 3% of all primary im-
munodeficiency disorders. It is diagnosed early in life, and many pa-
tients with severe WAS do not survive past 10 years of age without
definitive treatment.1 The classical WAS phenotype is characterized
by eczema, immunodeficiency, microthrombocytopenia, autoimmu-
nity, and malignancies.2 WAS is caused by mutations in the WAS220 Molecular Therapy: Methods & Clinical Development Vol. 19 Decem
This is an open access article under the CC BY license (http://creatigene3 (gene map locus Xp11.23-p11.22) that are expressed exclusively
in hematopoietic cells and play important roles in signaling and actin
cytoskeleton reorganization (reviewed in Blundell et al.4). Therefore,
most hematopoietic cells are affected to different degrees, causing the
phenotypic abnormalities observed in patients withWAS. Of all func-
tional defects, increased bleeding due to low platelet (PLT) counts is
the major challenge, with up to 30% of WAS patients suffering life-
threatening bleeding episodes.5
The only curative treatments forWAS patients are allogeneic hemato-
poietic stem and progenitor cell (HSPC) transplantation6 and autol-
ogous gene-modified HSPCs.7 Although HSPC transplantation is the
standard treatment procedure and is usually curative, the use of hu-
man leukocyte antigen (HLA)-matched HSPCs is associated with
acute morbidity and a high incidence of long-term complications,
although overall survival rates are continually improving.8–10 On
the contrary, lentiviral-based gene therapy (GT) clinical trials
observed limited toxicity and similar survival rates,7,11–14 making
this treatment a rational alternative therapeutic option. In these trials,
autologous CD34+ cells were genetically modified using a self-inacti-
vating (SIN) lentiviral vector (LV) expressing WASP under a 1.6-kb
fragment of the proximal promoter of the WAS gene.15 A general
consensus that arose from these clinical trials is that, although im-
mune deficiency was corrected, complete remission of microthrom-
bocytopenia was more difficult to achieve.16 Of note, HSPC trans-
plantation is more effective than GT in this aspect and is therefore
a drawback to overcome in new WAS GT products.16ber 2020 ª 2020 The Author(s).
vecommons.org/licenses/by/4.0/).
www.moleculartherapy.orgThe reasons behind the low PLT recovery achieved with GT in most
WAS patients are unclear. It could be due to the absence of the selec-
tive advantage of WASP-expressing PLTs,17 to the suboptimal WASP
expression in megakaryocytes (MKs), MK progenitors, and/or
PLTs,14 or to a combination of both factors. In this direction, our hy-
pothesis is that a physiological expression of WASP would improve
GT outcomes by preventing potential side effects of underexpression
or overexpression ofWASP alongMK differentiation. The exact func-
tions of WASP in PLTs remains largely unknown, but there is strong
evidence suggesting that it plays a critical role regulating MK differ-
entiation and PLT formation by inhibiting these processes in the
absence of the appropriated signals.18–20 This could sound contradic-
tory with the thrombocytopenia found inWAS patients, but it is actu-
ally a potential explanation for it. Indeed, PLTs produced in the
absence of WASP have not been developed properly and have a
reduced size, abnormal ultrastructure, and surface markers that
lead to their elimination in the spleen and other tissues. Therefore,
in order to generate normal PLT levels in WAS patients, we should
not only engraft with the appropriate levels of WASP-expressing
HSPCSs, but also mimic very closely the physiological expression of
WASP during MK development.
Different groups, including ours, have developed physiologically regu-
lated LVs for the treatment of WAS using different fragments of the
WAS-proximal promoter to drive the expression of WAS cDNA.15,21
These studies have shown hematopoietic-specific expression of the
differentWAS promoter-driven LVs that efficiently restoredWASP de-
fects in animal models.22,23 Later studies also showed improved safety
of these LVs by avoiding WASP expression in non-hematopoietic
cells24 and reducing genotoxicity.25 These works led to the approval
of the clinical trials mentioned above using the 1.6-kb WAS-proximal
promoter-driven LVs.15 However, as referred to previously, despite the
good clinical results, these trials showed suboptimal WASP expression
in PLTs and suboptimal recovery of microthrombocytopenia in most
patients. In an attempt to improve the behavior of WAS-proximal
promoter-driven LVs, our group generated AWE LVs26 that harbored
regulatory fragments from the two WAS promoters described in the
literature, i.e., the proximal promoter27 and the alternative promoter.28
The proximal promoter starts immediately upstream of the transcrip-
tion start site (GenBank: AC115618.3 sequence [Seq] 120189–121855),
and the alternative promoter is located 6 kb upstream (GenBank:
AC115618.3 Seq 114403–115000). The AWE LVs showed improved
enhanced GFP (EGFP) expression in myeloid, megakaryocytic, and B
cell lineages compared to WAS-proximal promoter-driven LVs.26
However, since the WAS cDNA contains regulatory sequences that
affect its expression pattern,29 it is fundamental to study the behavior
of the backbone of AW LVs expressingWAS cDNA in order to deter-
mine whether they achieve truly physiological expression. In this work
we use in vitro models to study whether WAS promoter-driven LVs
harboring sequences from the alternative promoter could improve
their therapeutic potential by mimicking more closely the WASP
expression pattern during megakaryocytic differentiation. Although
WASP expression levels are well documented in all mature blood
cells,30,31 the precise WASP expression profile in HSPCs alongMK dif-Molecular Theferentiation and PLT generation is mostly unknown. We therefore
analyzed first the WASP expression kinetic during MK differentiation
and then compared it with the expression pattern of the different LVs
driving the transgene through different regions of the WAS promoter,
including the LVs used in ongoing clinical trials for WAS. Our data
showed that all WAS promoter-driven LVs mimic very closely the
WASP endogenous expression kinetic during MK differentiation. We
also studied potential therapeutic improvements of the AW LVs
compared with the WW 1.6-kb (WW1.6) LVs, but could not find
any significant differences.
RESULTS
WASP Endogenous Expression Decreases during In Vitro
Megakaryopoiesis and Thrombopoiesis
Since we wanted to mimic WASP endogenous expression during MK
differentiation, we first established primary (Figure 1) and immortal-
ized (Figure 2) cellular models to study WASP expression patterns
through the MK differentiation process. MK progenitors
(CD34+CD41+), MKs (CD34CD41+CD42+), and PLTs (CD41+
CD42+FSClowSSClow) were routinely obtained from HSPCs (CD34+
CD41CD42) using the protocol depicted in Figure S1A, where hu-
man CD34+ cells were incubated with stem cell factor (SCF), throm-
bopoietin (TPO), and ROCK inhibitor as described in Materials and
Methods during 16 days. We could observe large cells that correlate
with immature MKs (Figure 1A, center) that finally extend proplate-
lets (Figure 1A, bottom) and are also associated with the phenotypical
acquisition of CD41a and CD42b megakaryocytic markers (Fig-
ure 1B). In addition, PLTs derived from HSPCs were functional in
response to thrombin (Figures 1C and 1D) and expressed similar
WASP protein levels as did those PLTs isolated from peripheral blood
of healthy donors (HDs) (Figure 1E), validating this cellular model to
study MK differentiation. We then analyzed WASP expression levels
(Figures 1F–1H) in MK progenitors, MKs, and PLTs at days 4, 8, 11,
and 16 of MK differentiation following gate strategy analysis repre-
sented in Figure S1B. Briefly, we first selected three different gates ac-
cording to forward scatter (FSC) and side scatter (SSC) (HPCs, MKs,
and PLTs), and then we further gated (1) undifferentiated CD34+
cells; (2) MK early progenitors (CD34+CD41+ cells); (3) MK progen-
itors (SSChighCD34+CD41+); (4) MKs (CD41+CD42+SSChigh); and
(5) PLTs (CD41+CD42+SSClow) as populations of interest. WASP
expression was calculated as the intensity ratio of WASP+ cells and
the background intensity of the isotype control of the selected popu-
lation (Figure S1B; see Materials and Methods). Our data showed a
clear WASP downregulation as the HSPCs differentiate to MK pro-
genitors (Figures 1F–1H; CD34+ versus CD34+CD41+, respectively),
a slight WASP increment when MK progenitors (CD34+CD41+
SSChigh) differentiate into early MKs (CD34+CD41+CD42+, day 4),
and a gradual downregulation as the MKs mature into PLTs (days
8, 11, and 16 and PLTs). The percentage of WASP+ cells showed
the same described tendency but in a more dramatic manner.
We then validated these results in K562 and MEG-01 cell lines previ-
ously characterized to give rise toMK-like cells (Figures 2A and 2B) as
determined by the acquisition of CD41a and CD42b megakaryocyticrapy: Methods & Clinical Development Vol. 19 December 2020 221
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www.moleculartherapy.orgmarkers (Figures 2C and 2E). K562 cells differentiated with phorbol
myristate acetate (PMA) and MEG-01 cells with valproic acid (VPA)
constitute classical models to study megakaryocytic differentiation,
which partially mimic some megakaryocytic characteristics in terms
of phenotype, maturation, and function.32 Interestingly, WASP
expression levels and percentage of positive cells were increased
upon MK differentiation in K562 cells (Figure 2D), while MEG-01
cells showed a clear downregulation along differentiation time (Fig-
ure 2F). These data indicate that K562 cells behave similar toMK pro-
genitors that differentiate into early MKs in the presence of PMA,
while MEG-01 cells resemble early MKs that give rise to mature
MKs and PLTs upon the addition of VPA.32 These two cell lines
therefore provide additional cellular models to study LV behavior
during MK differentiation.
WAS Promoter-Driven LVs Mimic WASP Expression Kinetics
during MK Differentiation and Restored PLT Actin Nodule
Formation
Once we established the three different human models of MK differen-
tiation and their WASP expression kinetics, we proceeded to analyze
the behavior of different second-generation LV backbones expressing
the EGFP reporter gene through different fragments of the WAS pro-
moter (Figures 3A and S2): theWELV21 harbors the 500-bp core of the
WAS proximal promoter, and the AWE26 and the cAWE (this work)
contained additional sequences from the WAS alternative promoter.
To analyze the physiological expression of these LVs duringMK differ-
entiation (Figure 3B), K562 cells (Figures 3C and S3A), MEG-01 cells
(Figures 3D and S3B), and HSPCs (Figures 3E and S4) were transduced
with the different LVs at a multiplicity of infection (MOI) of 1 for K562
and MEG.01 cells and at an MOI of 50 for HSPCs, obtaining a similar
efficacy of transduction (Figure S5). Their EGFP expression kinetics
(how the expression changes related to the expression of non-differen-
tiated cells, referred as fold expression and detailed in Figures S3 and
S4) were compared to that of endogenous WASP (filled bars in Figures
3C–3E) before and after MK differentiation. We observed similar be-
haviors of the three LVs, and all followed WASP expression kinetics
upon MK differentiation in K562 cells (Figure 3C; upregulation),
MEG-01 cells (Figure 3D; downregulation), and HSPCs (Figure 3E;
downregulation). Interestingly, in the HSPC model, the kinetics of
transgene expression at different times of MK differentiation were
also very similar (Figure 3E).Figure 1. WASP Endogenous Expression Decreases during In Vitro Megakaryo
(A) Representative bright-field images of hHSPCs before (top panel, 0–4 days) and after
panel, MKs releasing proplatelets, white arrows) of MK differentiation with TPO and SC
showing changes in morphology (FSChighSSChigh) and appearance of megakaryocytic m
Mature MKs (FSChighSSChighCD42+ cells) respond to thrombin by increasing intracellul
thrombin in obtainedMKs (FSChighSSChighCD42+ cells) and PLTs (FSClowSSClowCD42+
(FSClowSSClowCD41+CD42+) obtained from peripheral blood (PB, top left) and HSPCs (b
mean ± SEM (non-parametric Mann-Whitney test, two-tailed). (F) Representative dot p
populations in each plot display the IsC staining and colored populations display the W
population/MeFI of IsC, in the different populations during MK differentiation. CD34+
SSClowSSChigh) at days 4–8, mature MKs (CD34+CD41+CD42+) during 4–16 days of d
centage of WASP+ cells in the above-described populations. Represented data are me
two-tailed, compared to CD34+ expression levels) (n = 7).
Molecular TheWe next analyzed whether the physiological expression was main-
tained in the different WAS promoter-driven LVs expressing the
WAS cDNA, i.e., WW, AWW, and cAWW LVs (Figure 4A). In
this study, we used homozygous WASKO-K562 cells previously
generated by our laboratory20 (Figures 4B–4D) andWAS-null HSPCs
from aWAS patient (Figures 4F–4I). WASKO-K562 cells were trans-
duced with the different therapeutic LVs at an MOI of 1 to reach
similar transduction efficacies (as shown in Figure S5). WASP expres-
sion levels were analyzed in different populations (see Figure S6 for
details) after MK differentiation. Similarly to EGFP LVs, all WASP
LVs increased WASP expression upon MK differentiation, measured
as the percentage of WASP+ cells (Figure 4C) and as Median of Fluo-
rescence Intensity (MeFI) (Figure 4D). However, the WW LVs
showed higher WASP expression in resting K562 cells (Figure 4D,
WW) compared to endogenous WASP (Figure 4D, wild-type
[WT]), AWW, and cAWW LVs, indicating a more physiological
behavior of the AWW and cAWW LVs.
Interestingly, AWW- and cAWW-transduced WAS patient HSPCs
also recovered aWASP expression kinetic more similar to HDHSPCs
compared to those transduced with theWWLVs (Figures 4E and S7).
Indeed, although the expression levels ofWWLVs in undifferentiated
CD34+ were closer to those of HDs compared to AWW and cAWW
(Figures 4E and 4F), the expression kinetic at early days of differen-
tiation (day 4) were different (Figure 4E, red line). Nevertheless,
WASP expression levels in PLTs derived from WAS patient HSPCs
transduced with the different LVs (MOI of 50) were similarly rescued
(Figure 4F). In agreement with WASP expression levels, the restora-
tion of actin nodule33 formation in contact to immobilized fibrinogen,
which is severely compromised in patient PLTs, was also similar for
all LVs (Figures 4G and 4H).
Phenotypic Correction of WASKO Mice after Transplantation
with WW- and AWW-Transduced WASKO Murine HSPCs
(mHSPCs)
We next analyzed the therapeutic efficacy of AWW andWW LVs in a
mouse model of WAS,34 because cAWW LVs did not show significant
improvement in vitro compared with the AWW LVs. Lineage (Lin)
cells were isolated from bone marrow of WASKO mice (WASKO
mHSPCs) (see Materials and Methods) and transduced with AWW
and WW LVs at an MOI of 100. Both LVs achieved similarpoiesis and Thrombopoiesis
4–8 days (middle panel, MKs are indicated with white arrows) or 11–16 days (bottom
F without iROCK as indicated in Materials and Methods. (B) Representative plots
arkers (CD41a and CD42b) of HSPCs cultured with the MK differentiation media. (C)
ar calcium uptake (n= 3). (D) Expression of PAC-1 activation marker in response to
cells) (n = 3). (E) Representative histograms showingWASP expression levels of PLTs
ottom left). WASP expression (related to isotype control [IsC]) (right) is represented as
lots of endogenous WASP expression kinetics upon MK differentiation in vitro. Grey
ASP staining (n = 7). (G) Analysis of WASP expression, depicted as MeFI of WASP+
indicates HSPCs at day 0 (CD34+CD41CD42), MK progenitors (CD34+CD41+-
ifferentiation, and PLTs (CD41+CD42+FSClowSSClow) obtained at day 16. (H) Per-
an ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (non-parametric Mann-Whitney test,
rapy: Methods & Clinical Development Vol. 19 December 2020 223
Figure 2. Immortalized “MK-like” Cell Lines Are Relevant Models to Study Wasp Expression during MK Differentiation
(A) Scheme of megakaryocytic differentiation protocol of K562 cells (top) and associated morphological changes after 96 h of PMA incubation. (B) Diagram of MK differ-
entiation protocol of MEG-01 cells (top) and morphological changes after VPA addition. (C) Representative FACS plots of CD41a and CD42b megakaryocytic markers of
K562 cells in the absence or presence of PMA. (D) Percentage of WASP+ K562 cells andWASP expression without PMA treatment, analyzed in the total population (n = 4). (E)
Phenotypic changes of MEG-01 cells after VPA treatment expressing CD41a and CD42bmarkers. (F) Percentage of WASP+MEG-01 cells andWASP expression at 0, 7, 14,
and 21 days of VPA-megakaryocytic differentiation (n = 3). Represented data are means ± SEM, non-parametric Mann-Whitney test, two-tailed. **p < 0.01, ***p < 0.001.
Molecular Therapy: Methods & Clinical Developmenttransduction efficiencies (Lin AWW = 9.8 vector copy numbers/cell
[vcn/c]; Lin WW = 8.2 vcn/c) and expressed similar WASP levels
in WASKO mHSPCs (Figure S8B) and in their myeloid progeny (Fig-
ures S8E and S8F). Lethally irradiatedWASKOmice (9.5Gy) were then
injected with 3  105 AWW, WW, and mock WASKO mHSPCs as
well as with WT mHSPCs (C57BL/6 mice). After 2 and 6 months of
transplant, the SSC and FSC of cells from peripheral blood of the trans-
planted mice were analyzed (Figure 5A, left). The non-transduced
transplanted mice showed a higher number of granulocytes and lower
number of lymphocytes; meanwhile, theWT, AWW, andWW0.5 cor-224 Molecular Therapy: Methods & Clinical Development Vol. 19 Decemrected mice showed a normal distribution of the population in periph-
eral blood. 6 months later, treated mice were sacrificed in order to
analyze the ability of WW and AWW LVs to restore phenotypic and
functional defects (Figure 5). Vector copy numbers per cell in spleen,
bone marrow, and blood of transplanted mice ranged from 0.1 to 15,
showing efficient repopulation of recipient mice with transduced
AWW and WW Lin cells (Figure S9A). Both LVs were equally effi-
cient in restoring normal monocyte counts in a hemogram (Figure S9).
More importantly, transplanted mice achieved equivalent ratios of
B220+, Gr1+, and CD11b+ cells (Figure 5A, right) as compared tober 2020
Figure 3. EGFP-LV Expression Driven by WAS Promoter Mimic Endogenous WAS Protein Expression Kinetics during Megakaryocytic Differentiation
(A) Schematic representation of the second-generation LVs used in this study expressing enhanced GFP (EGFP). WE21 harbors the 500-bp core of the WAS proximal
promoter (GenBank: AC115618.3 Seq 121356–121851), while AWE26 (GenBank: AC115618.3: Seq 114605–114991 linker of 17bp/ Seq 121356–121851) and cAWE
(GenBank: AC115618.3: Seq 114403–115000 linker of 17 bp / Seq 121356–121851) contain additional 386-bp (Alt) and 597-bp (complete Alt) fragments of the WAS
alternative promoter, respectively. (B) Experimental protocols for the comparison of WASP endogenous levels with EGFP expression given by the different LVs during MK
differentiation in the different models. (C) Fold expression of endogenousWASP (black bars) and EGFP (colored bars) in K562 cells transduced withWE, AWE, and cAWE LVs
(MOI of 1) are related to the expression levels of CD41CD42 cells in the PMA+ condition (non-parametric Mann-Whitney test, *p < 0.05) (n = 4). (D) WASP and EGFP fold
(legend continued on next page)
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cells and increased levels of Gr1+ and CD11b+ cells. Similarly, the effi-
cacy of both LVs to rescue T cell responses (Figures 5B and 5C) and the
PLT counts (Figure 5D) were equivalent. These experiments validate
the efficacy of both WAS promoter-driven LVs as tools for WAS GT,
but they cannot differentiate any superiority.
Third-GenerationWAS-Driven LVs Have Improved Physiological
Expression and Restore Functional Defects In Vitro and In Vivo
We finally generated third-generation LVs based on the AWW and
investigated their behavior during MK differentiation as well as their
therapeutic activity in WASKO mice. We used the WW1.6 LV15 (Fig-
ure 6A, top; this is the LV used in ongoing clinical trials for WAS GT)
as the backbone to construct the third-generation AW LV by replacing
the full-length (1.6 kb)WAS proximal promoter by the chimericWAS
promoter (0.88 kb) containing sequences from the proximal and alter-
native promoter (Figures 6A and S2). WAS patient HSPCs were trans-
duced with WW1.6 and AW LVs at an MOI of 50 to achieve similar
transduction efficacies (WW1.6 = 2.6 ± 1.1 vcn and AW = 3.1 ± 1.6
vcn and Figure S5F). Transduced cells were differentiated into MKs
and the different subpopulations were analyzed for WAS expression
(Figures 6B and S9). As in second-generation LVs, the WASP expres-
sion dropped during MK differentiation in both LVs (Figure 6C). We
could not find any differences between both LVs in either terms of
expression kinetics (Figures 6C) or in PLT expression levels (Fig-
ure 6D). However, a comparison of the WASP expression levels of
each vector with WASP expression in PLTs from HDs showed signif-
icant differences with PLTs derived from 1.6WW-transduced HPSCs,
but not with PLTs derived from AW-transduced HPSCs, although
more experiments are necessary to demonstrate this.Wenext evaluated
the functional restoration ofMKs and PLTS derived fromWW1.6- and
AW-transduced WAS HSPCs by measuring PAC-1 expression in
response to thrombin (Figures 6E), the formation of actin nodules (Fig-
ures 6F and 6G), or calcium uptake (Figure S11). We found a very
similar improvement with both LVs, restoring the response of MKs
and PLTs to thrombin, as well as the ability of PLTs to form actin nod-
ules per PLT. Similar findings were also observed for the restoration of
podosome formation and clustering on macrophages derived from
WAS HSPCs transduced with WW1.6 and AW LVs (Figures 6H–
6K), which exhibited similar WASP expression in the CD33+CD14+
cells obtained in vitro (Figure 6I). We finally analyzed the therapeutic
efficacy of WW1.6 and AW LVs in the WASKO mouse model.
WASKO mHSPCs were isolated from bone marrow, transduced with
both LVs, and transplanted into irradiated WASKO mice (Figure 6l).
Mock-transduced WASKO mHSPCs and WT mHSPCs were injected
into control mice. 7 months later, treated mice were sacrificed to
analyze the ability of WW1.6 and 0.88-kb AW (AW0.88kb) to restore
functional defects. Both LVs were equally efficient in restoring spleen
size (Figure 6M) and PLT counts (Figure 6N).expression at days 7 and 14 of MK differentiation of MEG-01 cells treated with VPA (non-
(n = 4). (E) WASP and EGFP fold expression in human CD34+, CD41+SSClow, CD41+SS
EGFP, colored bars) at 4, 8, 11, and 16 days after in vitroMK differentiation (n = 10). Non
two-way ANOVA, Bonferroni post-test (***p < 0.001) compared to wild-type (WT). All d
226 Molecular Therapy: Methods & Clinical Development Vol. 19 DecemDISCUSSION
GT has demonstrated to be a real therapeutic alternative for WAS pa-
tients.7,11–14 The current GT approaches for WAS used autologous
HSPCs (CD34+) genetically modified using a 1.6-kb WAS-proximal
promoter-driven LV and transplanted back into the patients. The clin-
ical efficacy of these LVs has been clearly demonstrated since treated
patients have shown a reduction of infections and diminished severity
of eczema as well as reduced frequency and severity of bleeding epi-
sodes. However, although the bleeding was reduced or completely cor-
rected in most patients,7,14 microthrombocytopenia persisted and
normalized PLT counts were not achieved in most patients.11,14,16
The reasons behind the low PLT recovery achieved with GT compared
with the other immune functions are unclear. It was postulated that
PLT recovery could correlate with the number of transduced HSPCs
reinfused. In this case, the absence of a potent selective advantage in
MKs and MK progenitors expressing WASP could be a contributory
factor in contrast to lymphocytic lineages.17 Other hypotheses are
that the WW1.6 LV achieved suboptimal levels of WASP expression
per copy of integrated vector in MKs, MK progenitors, and/or
PLTs.14 At the same level of HPC transduction, it may be possible to
correct the function of lymphoid cells but not that of MK lineage cells.
Furthermore, PLTs with suboptimalWASP levels could undergo accel-
erated destruction in the spleen and in other organs.
An ideal GT vector for WAS should not only transduce HSPCs effi-
ciently, but alsomimic endogenousWASPexpressionduringHSPCdif-
ferentiation to the different hematopoietic lineages. Our hypothesis is
that physiological expression of WASP during MK differentiation and
in PLTs would improve GT outcomes. The aim of this work was there-
fore to investigate WASP expression along MK differentiation and to
definewhich therapeutic LVmimicsmore closely represent this pattern.
Although WASP expression levels are well established in most mature
blood cells,30,31 the WASP expression kinetics during MK differentia-
tion and thrombopoiesis are not largely studied.We used immortalized
cellular models (K562 and MEG-01) as well as primary HSPCs to
investigate WASP expression kinetics during these processes. Our
data showed an initial decrease in WASP expression from HSPCs to
MKprogenitors, a slight increasewhen they are differentiated into early
MKs, and a gradual downregulation as these MKs mature into PLTs.
This WASP expression kinetic has never been described before and
it could be of relevance for normal MK differentiation and thrombo-
poiesis. We corroborated this expression pattern on two immortalized
cell lines, K562 and MEG-01, that resemble different stages of MK dif-
ferentiation. K562 cells have been described previously as amultipotent
myeloid-MK cell line for the study of early events in MK differentia-
tion,35,36 while MEG-01 cells are defined as an immature MK cell
line able to differentiate into mature MKs and PLTs.37,38 Interestingly,
upon MK differentiation, K562 cells mimicked the differentiationparametric Mann-Whitney test, *p < 0.05, **p < 0.01) related to undifferentiated cells
Chigh, and CD41+CD42+ cells derived from HSPCs (endogenous WASP, black bars;
-parametric Mann-Whitney test, two-tailed (#p < 0.05, ##p < 0.01, ###p < 0.001) and
ata are represented as mean ± SEM.
ber 2020
Figure 4. WAS Promoter-Driven LVs Harboring Sequences from the Alternative Promoter Rescue WASP Expression Kinetics in Human Cellular Models of
WAS
(A) Schematic representation of second-generation LVs expressing WAS cDNA. WW21 harbors the 500-bp core of the WAS proximal promoter, AWW,26 and cAWW (the
present study). LVs contain an additional 386- and 600-bp fragment of the WAS alternative promoter, respectively (see Figure S2 for details). (B) Experimental diagram of
K562WASKO transduced withWAS LVs (MOI of 1) and differentiated toMK-like cells with PMA stimulation. (C and D) Graphs showing the percentage ofWASP+ cells (C) and
WASP expression levels (D) in WT K562 cells (black bars) and in WASKO K562 cells transduced with WW (gray bars), AWW (blue bars), and cAWW (green bars) after MK
differentiation with PMA in CD41CD42 and CD41+ populations (n = 7). (E) Graph shows relative WASP expression in HD CD34+ cells and WAS patient cells transduced
with WW (gray), AWW (blue), and cAWW (green) (MOI of 50) at 4, 8, 11, and 16 days of MK in vitro differentiation (n = 4). ***p < 0.001, two-way ANOVA, Bonferroni post-test
(compared to same day and conditions of HD). (F) Graph showing WASP expression levels of PLTs derived from WAS patient’s HSPCs transduced with WW, AWW, and
cAWW related toWT-drivenWASP expression. (G) Representative confocal images of actin nodule formation of platelets derived fromHDCD34+ cells (left), WAS patient cells
(second left), andWAS patient cells transduced withWW (middle), AWW (second right), and cAWW (right). Several nodules are indicated with white arrows. (H) Quantification
of actin nodule per PTL counted in images from (G). Photographs analyzed: HD, 31; WAS, 6; WW, 17; AWW, 26; cAWW, 22. Non-parametric Mann-Whitney test, two-tailed.
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Figure 5. WW- and AWW-Transduced WASKO mHSPCs Rescue Phenotypic Defects of WASKO Mice
(A) Restoration of the hematopoietic profile in mice transplanted with WW- and AWW-transduced WASKOmHSPCs (MOI of 100; WWmHSPCs = 8.2 vcn/c and AWW= 9.8
vcn/c). Side and forward scatter (left) of cells from PB of the transplanted mice 2 (left, up) and 6 (left, down) months after transplant. The non-transduced (NT) transplanted
mice showed a higher number of granulocytes and a lower number of lymphocytes; meanwhile, the WT mHSPC and WASKO mHSPC AWW- and WW-corrected mice
showed a normal distribution of the population in PB. 6 months post-transplant (right graph), mice were sacrificed and PB was analyzed for vcn/v (see Figure S9), CD45.2
(donor cells), and lineage markers CD3 (T cells), CD220 (B cells), Gr1+ (granulocytes), and CD11b (myeloid cells). Mice per group: WT = 2, NT = 2, AWW= 3,WW0.5 = 3. *p <
0.05, by unpaired t test. Data represent mean ± SEM. (B–D) Phenotypic rescue of WASKO mice after transplantation with WW- and AWW-transduced WASKO mHSPCs
(MOI of 100;WWmHSPCs = 8 vcn/c and AWW=6 vcn/c). (B andC)Micewere sacrificed after 3months, and T cell proliferation assay (CFSE) (B) and IL-2 production (C) were
measured after 5 or 3 days, respectively, after stimulation with anti-CD3 (1 mg/mL) by ELISA. One-tailed Mann-Whitney test. Data represent mean ± SEM (WT, N = 2; NT/KO,
N = 2; AWW, N = 5; WW, N = 4). *p < 0.05, **p < 0.01. (D) Number of platelets in blood of transplanted mice compared with WT and NT (WT, N = 2, NT, N = 1, AWWN= 4,
WW0.5 = 3). Copies/cell (cc) in spleen: AWW, 1.9 ± 1.1 cc; WW0.5, 1.8 ± 0.4 cc. Data represent mean ± SEM.
Molecular Therapy: Methods & Clinical Developmentphase from MK progenitors into early MKs, increasing WASP levels,
while MEG-01 cells mimic the differentiation stage from early MKs
into mature MKs and PLTs, reducing WASP expression. The exact
role of these changes in WASP expression during MK differentiation
is not clear; however, because the absence of WASP increases PLT pro-
ductionwith abnormal phenotype,18–20 it could be relevant for GT stra-
tegies to mimic it. Therefore, our hypothesis is that WAS GT strategies
should not only achieve good WASP expression levels on PLTs and
MK differentiated cells but also mimic the endogenous expression ki-
netic during MK differentiation.
Once we had established the physiological WASP expression pattern
during megakaryopoiesis and thrombopoiesis, we analyzed the
behavior of different LVs harboring different fragments of the WAS
proximal and alternative promoters. Our previous data indicated
that an LV driving EGFP through aWAS promoter (AWE), contain-
ing a 386-bp fragment of the alternative promoter immediately up-
stream of the 500-bp WAS-proximal promoter, increased GFP
expression in myeloid cells and mature MKs.26 The alternative pro-
moter is located 6 kb upstream of the proximal promoter and con-228 Molecular Therapy: Methods & Clinical Development Vol. 19 Decemtains several transcription factor binding sites (TFBSs) shared with
the proximal promoter (Sp-1, AP-2, c-Myb, and EGR2) and others
that are unique (C/EBP, CP1, Ets-2, and GCF).28,39 The differences
found between both promoters suggest that their activity may vary
depending on the cell lineage and the state of differentiation or devel-
opment. In particular, the presence of TFBSs for C/EBP, CP1, c-Myb,
Ets-2, and PU.1 suggest that the alternative promoter could play
important roles in the myeloid and megakaryocytic lineages.40–42
However, the 386-bp fragment of the alternative promoter does not
include binding sites for C/EBP and CP1, which are required for
higher expression levels in K562 cells.39 Based on these data, we
generated new WAS-driven LVs (cAWE and cAWW) harboring
the complete alternative promoter and the 500-bp proximal promoter
and compared their behavior with the WAS-proximal promoter LVs
(WE and WW), the shortest version of the alternative promoter
(386 bp), and the 500-bp proximal promoter (AWE and AWW).
The different second-generation LV backbones (W-, AW-, and
cAW-) were studied based on their ability to express EGFP and
WAS cDNA during MK differentiation and analyzing whether this
expression followed the same kinetic as that of the endogenousber 2020
(legend on next page)
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Molecular Therapy: Methods & Clinical DevelopmentWAS protein. Although all EGFP-expressing LVs mimicked the
WASP expression pattern along MK differentiation, the WE LV
was slightly weaker than the AWE and cAWE LVs. Interestingly,
the expression of WAS cDNA altered the physiological behavior of
the 500-bp WAS-proximal promoter LVs (WW) at early stages of
MK differentiation, while the AWW and the cAWW LVs still fol-
lowed the WASP endogenous pattern. Our finding indicates that
the 500-bp WAS-proximal promoter-driven LVs lead to a WASP
overexpression at early stages of MK differentiation (CD34+CD41+
CD41 to CD34+CD41+CD42+), while AW and cAWW achieve
more physiological expression. A detailed analysis of WASP kinetics
along MK differentiation revealed a more pronounced decay of
WASP expression of the WAS-proximal promoter-driven LVs
compared to the WAS-proximal and alternative promoters and to
endogenousWASP. However, we could not observe significant differ-
ences in the behavior of AWW versus cAWW LVs. We therefore
concluded that the insertion of regulatory sequences from the WAS
alternative promoter into the 500-bp proximal promoter improved
physiological expression of therapeutic LVs during MK development.
Despite their improved physiological expression, we could not detect
significant differences between the second-generation WW and
AWW LVs in terms of functional correction either in animal models
or in the HSPCs of WAS patients. Importantly, our analysis showed
that LVs expressing the WAS cDNA through the proximal and alter-
native promoter (in a second- or third-generation backbone) are able
to (1) restore actin nodules in PLTs (Figures 4G and 4H); (2)
normalize WAS mice blood populations upon transplantation with
transduced WASKO Lin cells (Figures 5A and S9); (3) improve
T cell responses (Figures 5B and 5C); (4) improve PLT counts
(Figures 5D and 6N); (5) reduce spleen size (Figure 6M); (6) restore
podosome clustering of macrophages derived from transducedFigure 6. Third-Generation WAS-Driven LVs Mimic Endogenous WASP Expres
In Vitro and In Vivo
(A) Third-generation LVs used for the study. WW1.6 referred the current clinical vector h
Seq 120189–121855) and AW that includes an alternative promoter previously describ
from a WAS patient were transduced with the third-generation LVs at an MOI of 50 (WW
functional restoring were analyzed after in vitroMK differentiation. (C) Relative WASP exp
days 4, 8, 11, and 16 of MK differentiation. Represented data are means ± SEM. Mann
PLTs (CD41+CD42+FSClowSSClow) derived fromHD,WAS_WW1.6, andWAS_AWHSP
gated MKs (CD42+FSChighSSChigh) (left) and PLTs (CD42+FSClowSSClow) (right) from H
means ±SEM.Mann-Whitney test, two-tailed, *p < 0.05 (n = 3). (F) Confocal images of ac
nodules. (G) Quantification of actin nodules/platelet in the transduced cell photographs
Whitney test, two-tailed. (H) Schematic diagram showing the procedure to study podo
showing CD14 expression after monocytic differentiation (DIF+) in the CD33+ populati
derived from healthy (black bars),WAS patient cells (set as control, not shown), andWAS
the end of the differentiation (day 20). Non-parametric Mann-Whitney t test, not significa
podosomes in a cluster structure (composed for at least 20 podosomes). Photographs fr
patient (12 photographs, 195 cells), WW1.6 (12 photographs, 110 cells), AW (14 photo
Representative images of podosomes in clusters from confocal microscopy. Cells obtain
nuclei (DAPI, blue), actin (red), and vinculin (green) were stained. (L) Schematic diagra
transduced cells (Lin AW = 5 vcn/c, Lin WW1.6 = 8 vcn/c). (M) Graphs showing splee
12 weeks old, left graph) andWASKOmice transplanted with AW- andWW1.6-transduc
inWT andWASKOmice as well as inWASKOmice transplanted with LinWASKO cells
0.31 vcn/c and WW1.6 = 0.58 ± 0.30 vcn/c.
230 Molecular Therapy: Methods & Clinical Development Vol. 19 DecemWAS-null human hHSPCs (hHSPCs) (Figures 6H–6K); and (7)
restore calcium uptake dynamics after thrombin stimulation of
PLTs derived from transduced WAS-null hHSPCs (Figure S11).
Still, since theAWWLVs confer amorephysiological expression profile
during MK differentiation, we reasoned that it would be relevant to
investigate the potential of third-generation LVs harboring the shorter
version of the alternative and proximal promoter (AW) as another op-
tion to the existing therapeutic LV for WAS GT, i.e., WW1.6, which
drives the expression ofWAS cDNA through a 1.6-kb fragment of the
WAS-proximal promoter. Contrary to what was found with the LVs
harboring the 0.5-kb proximal promoter, the LV used in the ongoing
clinical trials for WAS, i.e., the WW1.6 LV, was as good as the AW
mimicking the WASP endogenous pattern. We finally showed a very
similar therapeutic efficacy of both third-generation LVs WW1.6 and
AW in WAS patient HSPCs as well as in WAS mouse models. These
data indicate that the thrombocytopenia defects found in WW1.6 LV-
treated patients is not duenon-physiologicalWASP expressionkinetics,
and they favor the hypotheses of low numbers of engrafted WASP+
HSPCs. In addition, we cannot completely exclude that WASP expres-
sion levels are inadequate for in vivo production of PLTs in humans,
since our in vitromodels may not fully model these steps.
In summary, in this work we have identified theWASP expression ki-
netics during MK differentiation, which show an initial decrease in
WASP expression as HSPCs differentiate into MK progenitors, a
slight increase when progenitors differentiate into early MKs, and a
continuous downregulation as these MKs mature into PLTs. Based
on these data, we have shown that the 500-bp WAS-proximal pro-
moter-driven LVs improved their physiological behavior after inclu-
sion of regulatory sequences from the alternative promoter. However,
the WW1.6 LV was as good as the AW in mimicking the WASPsion Kinetics during MK Differentiation and Restore Functional Defects
WW1.6 that includes the complete WAS 1.6-kb proximal promoter15 (AC115618.3
ed (AC115618.3: Seq 114605–114991/17 bp/ Seq 121356–121851).26 (B) HSPCs
1.6 = 2.61 ± 1.13 vcn/c and AW = 3.16 ± 1.61 vcn/c), and WASP expression and
ression of HD,WAS_WW1.6, andWAS_AW in the CD41+CD42+ gated population at
-Whitney test, two-tailed, ***p < 0.001 (n = 5). (D) WASP relative expression levels in
Cs compared to those of HD-derived PLTs. *p < 0.05 (n = 4). (E) PAC-1 expression of
D-, WAS-, WAS_WW1.6-, and WAS_AW-derived HSPCs. Represented data are
tin nodules in platelets derived fromHSPCs.White arrows indicate examples of actin
analyzed; **p < 0.01, ***p < 0.001. HD = 31, WAS = 6; WW1.6 = 5, AW = 9. Mann-
some restoration in monocytes derived from WAS patient’s HPSCs. (I) Histograms
on (left). WASP expression (right) was determined in the CD33+CD14+ population
patient cells transduced withWW1.6 (light-blue bars) and AW (dark-blue bars) LVs at
nt (WT, N = 3; WW1.6 and AW, N = 4). (J) Graph shows the percentage of cells with
om three different experiments were analyzed: HD (18 photographs, 338 cells), WAS
graphs, 198 cells). Non-parametric Mann-Whitney t test, two-tailed, **p < 0.05. (K)
ed in vitrowere incubated overnight onto fibronectin-coated chambers at 37C, and
m of transplant procedure of WASKO mice with AW- and WW1.6 Lin WASKO-
n size (longitudinal size measured in centimeters) of WT and WASKOmice (mice 10–
ed LinWASKO cells (18–20 weeks old, right graph). (N) Graph showing PLT counts
transduced with AW andWW1.6 LVs. Vector copies analyzed in spleen: AW = 1.03 ±
ber 2020
www.moleculartherapy.orgexpression pattern and also in restoring functional defects of HSPCs
in WAS patients and WASKO mice models. Collectively, our data
indicated that the WW1.6 and AW LVs are able to mimic WASP
endogenous expression patterns during MK differentiation. We pro-
pose to use the AW LVs for a clinical trial for WAS GT in order to
investigate potential therapeutic benefits over the WW1.6 LVs.
MATERIALS AND METHODS
Cells
293T cells (CRL11268; American Type Culture Collection, Rockville,
MD, USA) were maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Thermo Fisher Scientific, Waltham, MA, USA) with Gluta-
MAX supplemented with 10% heat-inactivated fetal bovine serum
(FBS, Sigma-Aldrich, St. Louis, MO, USA) and antibiotics. The hu-
man cell line K562 (lymphoblasts from bonemarrow chronic myelog-
enous leukemia [CML]) was obtained from ATCC (CCL-243) and
maintained in RPMI 1640 media (Invitrogen) supplemented with
10% FBS at 5% CO2 and 37C. Autologous CD34
+ cells were collected
from mobilized peripheral blood (after cryopreservation of an un-
modified backup stem cell harvest). The WAS patient carried the
WAS mutation c.58C>Tp.(Gln20*). Cells were grown for 6 days in
StemSpan media (STEMCELL Technologies, Vancouver, BC, Can-
ada) supplemented with 1% penicillin/streptomycin, 100 ng/mL re-
combinant human Stem Cell Factor (SCF), 100 ng/mL fms-related
tyrosine kinase 3 ligand (Flt-3L), 20 ng/mL thyroperoxidase (TPO),
20 ng/mL interleukin (IL)-6 (all from PeproTech, NJ, USA), 1 mM
StemRegenin 1 (SR1) (Cayman Chemical, MI, USA), 500 nM
UM729 or UM171 (STEMCELL Technologies), and 10 mM 16,16-
dimethyl prostaglandin E2 (dmPGE2) (Cayman Chemical). All cur-
rent regulations have been complied for the experimentation with pa-
tient samples, following the current Spanish legal regulations on
research with humans (Real Decreto 561/1993 of April 16 (BOE
1993; no For usage of human CD34+ HSPCs from HDs andWAS pa-
tient, informed written consent was obtained in accordance with the
Declaration of Helsinki and ethical approval from the Great Ormond
Street Hospital for Children NHS Foundation Trust and the Institute
of Child Health Research Ethics (08/H0713/87).
Bone marrows of C57BL/6J and B6.129S6-Wastm1Sbs/J mice were har-
vested from the femurs and tibias, and Lin progenitors were isolated
with magnetic beads using a lineage cell depletion kit (130-090-858,
MACS, Miltenyi Biotec, Germany) following the manufacturer’s in-
structions. 1  106 cells/mL were cultured in StemSpan media
(STEMCELL Technologies) supplemented with 1% penicillin/strep-
tomycin, 1% glutamine, 100 ng/mL murine (m)SCF, 20 ng/mL
mFlt-3L, 20 ng/mL mIL-3 and 20 ng/mL mIL-6 (PeproTech).
Human PLTs were obtained by centrifugation of peripheral blood at
200 g for 20 min. The supernatants were recovered and centrifuged
at 1,000 g for 10 min in the presence of prostacyclin I2 (0.1 mg/mL,
Abcam ab120912). The pellet was resuspended in modified Tyrode’s
buffer (TB; 150 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3, 0.1%
glucose, 0.1% BSA, 5 mM HEPES, 1 mM CaCl2, and 1 mM MgCl2
[pH 7.3]) containing 0.1 mg/mL prostacyclin.Molecular TheAnimals
C57BL/6J and B6.129S6-Wastm1Sbs/J mouse colonies were already es-
tablished at the animal facility of University College London (UCL)
(original stock obtained from The Jackson Laboratory, USA).
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice were obtained from The Jack-
son Laboratory (USA). All animals were handled in strict accordance
with good animal practice as defined by UK Home Office Animal
Welfare Legislation, and all animal work was approved by the Insti-
tutional Research Ethics Committee (Institute of Child Health, Uni-
versity College London, UK) and performed under project license
nos. 70/7024 and 2557.
LV Plasmid Constructs
WWandWE carry a 0.5-kb fragment of theWAS-proximal promoter
(GenBank: AC115618.3 Seq 121356–121851) driving the expression
of human WAS21 and EGFP cDNAs, respectively. AWW and AWE
were engineered by inserting a 0.38-kb fragment of theWAS alterna-
tive promoter22 immediately upstream of the 0.5-kb WAS proximal
promoter in the WW vector26 (GenBank: AC115618.3: Seq
114605–114991 linker of 17-nt fragment containing the EcoRI site
and Seq 121356–121851) driving the expression of human WAS
and EGFP, respectively. cAWE contains the complete alternative pro-
moter (0.69 kb) upstream of the 500-bp proximal promoter (Gen-
Bank: AC115618.3: Seq 114403–115000 linker of 17-nt fragment con-
taining the EcoRI site Seq 121356–121851) for the expression of
EGFP. The cAWW plasmid was obtained after insertion of WAS
cDNA in the cAWE backbone (instead of the EGFP sequence) (re-
striction enzymes BamHI and KpnI) (New England Biolabs), by stan-
dard cloning techniques. All of these LVs share the SIN lentiviral
backbone described by Zuffery et al.43
For the construction of the third-generation AW LVs, we used the
WW1.6 plasmid15 (kindly provided by Généthon) as backbone and re-
placed the ClaI/BstXI fragment containing the 1.6-kb WAS-proximal
promoter (GenBank: AC115618.3 Seq 120189–121855), by the ClaI/
BstXI fragment from the AWW LV26 harboring the WAS alternative
and proximal promoter (0.38+0.5 kb) (GenBank: AC115618.3: Seq
114605–114991 a linker of a linker of 17-nt fragment containing the
EcoRI site Seq 121356–121851).
LV Production, Titration, and MOI
LV particles were produced by polyethylenimine (PEI) (Sigma-Al-
drich, no. 408727) or lipoD293 (SignaGen Laboratories, Gaithers-
burg, MD, USA) as previously described.44 Briefly, for second-gener-
ation LVs, 293T packaging cells were transfected with packaging
(pCMVDR8.91), envelope (pMD2.G) (http://www.addgene.org/
Didier_Trono/) , and the desired vector plasmids (WW, WE,
AWW, AWE, cAWW or cAWE). The third-generation LVs were ob-
tained by the following four transfection plasmids: CTE (gag/pol),
pMD2.G (envelope), pRev plasmids, and vector plasmid (AW and
WW1.6). The producer cells were cultured for 48 and 72 h, and the
viral supernatants were collected at those times and filtered through
a 0.45-mm filter (Stericup and Steritop sterile filters, Merck Millipore,
MA, USA). The viral particles were then concentrated byrapy: Methods & Clinical Development Vol. 19 December 2020 231
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Laboratory, Weaverville, NC, USA) at 40,000 rpm for 2 h at 4C, and
the viral pellets were resuspended in StemSpan media (STEMCELL
Technologies) for 1 h on ice, aliquoted, and immediately frozen at
80C.
Viral titers (transduction units [TU]/mL) were calculated using quan-
titative PCR. Briefly, 293T cells were transduced with serially diluted
amounts of LV. Genomic DNA was isolated (105 cells equivalent to
0.6 mg of genomic DNA) and the copy number of LVs integrated
was measured using a standard curve (from 102 to 107 copies) of
plasmid DNA. Titers obtained for the therapeutic LVs were as follows:
WW, 7.91 107 to 6.35 109 TU/mL; AWW, 1.58 108 to 8.67 109
TU/mL; cAWW, 1.07 108 to 7.24 109 TU/mL;WW1.6, 1.13 109
to 3.47  109 TU/mL; AW, 6.52  108 to 3.31  109 TU/mL.
Immortalized cell lines and primary hHSPCs were incubated with the
different viral supernatants for 5 h at 37C 5% CO2. Transduction
levels of the cells were determined by flow cytometry 48–72 h after
transduction.
A different MOI was established for the different cell types. K562 and
MEG-01 cells were transduced at an MOI of 1, hHSPCs at an MOI of
50, and mouse HSPCs at an MOI of 100.
Megakaryocytic Differentiation of K562 and MEG-01 Cell Lines
105 K562 cells/mL were plated on a six-well plate and incubated with
30 nM of PMA (phorbol 12-myristate 13-acetate, Sigma-Aldrich)
during 96 h without media exchange. DMSO was added as negative
control of differentiation. 105 MEG-01 cells/mL were incubated
with 2 mM VPA (Sigma-Aldrich) during 21 days. Media were
changed every 2–3 days with fresh VPA. Cells were detached with
TrypLE (5 min, 37C) for flow cytometry analysis.
Megakaryocytic Differentiation of HSPCs (CD34+)
2.5 105 cells/well were seeded in a 24-well plate in a final volume of
1 mL of StemSpan serum-free expansion medium (SFEM) (STEM-
CELL Technologies) supplemented with TPO (50 ng/mL) and SCF
(5ng/ml) and added to the cells on days 0, 4, 8, 11, and 16. The
concentration of the cells was always kept below 1 106 cells/mL. In-
hibitor of the kinase ROCK (iROCK) was added to the medium pre-
viously described at day 8 of differentiation to a final concentration of
10 mM. Cells were harvested at different time points for staining with
anti-human CD34-phycoerythrin (PE)-Cy7, anti-human CD41a-PE,
and anti-human CD42b-allophycocyanin (APC) (all from eBio-
science) and analyzed by flow cytometry.
Activation Assay: Calcium Flux
MKs and PLTs derived from HSPCs were washed at 900  g during
5 min and resuspended in TB (Sigma). Cells were stained with
CD42b-APC during 20 min at room temperature (RT) and washed
with TB. Then, cells were incubated with calcium-eFluor 514 (eBio-
science) at a final concentration of 5 mM during 40 min at 37C. Cells
were washed in TB and acquired on a FACsCanto II flow cytometer232 Molecular Therapy: Methods & Clinical Development Vol. 19 Decemduring 30 s to establish basal levels (t = 0). Then, thrombin (2 U/mL)
was added and acquired immediately during 90 s.
Activation Assay: Binding of PAC-1
MKs and PLTs from HSPCs were centrifuged at 900 g, washed, and
resuspended in TB with calcium andmagnesium. Cells were activated
with thrombin (2 U/mL) during 10 min at RT and stained anti
CD42b-APC and anti PAC-1-fluorescein isothiocyanate (FITC) (all
from eBioscience) and incubated during 25 min at RT. The cell sus-
pension was washed with TB, fixed with 0.25% paraformaldehyde
(PFA) in TB, and acquired on a FACSCanto II flow cytometer.
Actin Nodule Formation Assay
MKs and PLTs derived from HSPCs were harvested and washed in TB
in the presence of prostacyclin I2 (Abcam, Cambridge, UK). Cells were
seeded in chamber slides (Lab-Tek II chamber slide, Thermo Fisher
Scientific) pre-treated with fibrinogen (10 m/mL, Sigma-Aldrich), and
they were left to adhere for 30 min at 37C without stimuli. Chambers
were washed briefly with PBS and fixed with 10% formalin for 10 min
at RT. After three washes with PBS, fixed cells were treated with 50mM
NH4Cl for 10 min for quenching residual fluorescence, washed three
times, and permeabilized with 0.1% Triton X-100 for 10 min. After
washing, cells were incubated with rhodamine-phalloidin (1:200,
Thermo Fisher Scientific) during 30 min, washed, and mounted with
ProLong Gold antifade reagent (Thermo Fisher Scientific). Images
were acquired on a Confocal Laser Zeiss LSM 710 microscopy and
analyzed with ImageJ (National Institutes of Health [NIH], Bethesda,
MD, USA). Actin nodules per PLT were counted for WT (31 images),
WAS patient (6), WW (17), AWW (26), cAWW (22), WW1.6 (4), and
AW (9) in three independent experiments.
Myeloid Differentiation of HSPCs (CD34+)
Briefly, 50,000 HSPCs were cultured in low-attachment 24-well plates
with StemSpan (STEMCELL Technologies) supplemented with Flt-
3L (50 ng/mL), SCF (200 ng/mL), IL-3 (10 ng/mL), IL-6 (50 ng/
mL), and macrophage colony stimulating factor (M-CSF) (50 ng/
mL) (all from PeproTech) during 21 days. Media were renewed every
2–3 days. Monocytic differentiation was determined by the increment
of FSC and SSC and expression of CD33-PE and CD14-APC (all from
eBioscience) by flow cytometry.
Podosome Immunostaining
200,000 HSPC derived-macrophages were cultured overnight over
Lab-Tek II chamber slides (Thermo Fisher Scientific) coated with
10 mg/mL fibronectin (Thermo Fisher Scientific). On the next day, cells
were fixed with 4% formaldehyde, permeabilized with 0.1% Triton X-
100 in PBS, and blocked with PBS+1% BSA. Then, cells were incubated
with phalloidin-Alexa Fluor 568 (Thermo Fisher Scientific) (20min) to
detect F-actin, washed, and incubated with anti-vinculin antibody
(hVIN-1) (Sigma-Aldrich, St. Louis, MO, USA) (20 min). After
washing, the cells were incubated with a goat anti-mouse immunoglob-
ulin G (IgG) conjugated toAlexa Fluor 488 (Invitrogen) andDAPI, and
they were placed on slides with mounting media (ProLong Gold,
Thermo Fisher Scientific). Images were captured on a Zeiss LSM 710ber 2020
www.moleculartherapy.orginverted confocal microscope (Zeiss, Oberkochen, Germany). Images
were processed in Fiji-ImageJ program (NIH, Bethesda, MD, USA).
Clusters of podosomes were defined as a zone of at least 20 podosomes.Purification, Transduction, and Transplantation of Lin– Cells
Bone marrow of C57BL/6J and B6.129S6-Wastm1Sbs/J mice was har-
vested from the femurs and tibias, and Lin progenitors were isolated
with magnetic beads using a lineage cell depletion kit (130-090-858,
MACS, Miltenyi Biotec, Germany) following the manufacturer’s in-
structions. 1  106 cells/mL were cultured in StemSpan media
(STEMCELL Technologies) supplemented with 1% fetal calf serum
(FCS) (Invitrogen), 1% penicillin/streptomycin, 100 ng/mL murine
SCF, 20 ng/mL mFlt-3L, 20 ng/mL mIL-3, and 20 ng/mL mIL-6. Iso-
lated murine Lin cells were transduced for 16–18 h with the different
LVs (MOI of 100). A sample was retained and further cultured for
72 h to determine transduction efficiency (integrations per cell),
in vitro differentiation into myeloid or dendritic cells, and for trans-
plantation into B6.129S6-Wastm1Sbs/J mice.WT, non-transduced, and
transduced WASKO Lin cells (3  105 to 1  106) were inoculated
intravenously into lethally irradiated mice (split dose of 9.5 Gy). An-
imals were sacrificed by using CO2 inhalation and cervical dislocation
3–7 months after transplants. Percentage of myeloid populations and
expression of WASP was analyzed.LV Integrations in Transplanted WASKO Mice
Genomic DNA from spleens of transplanted WASKO mice was ex-
tracted using the DNeasy blood and tissue kit (QIAGEN, Hilden,
Germany). The quantitative PCR was performed in a CFX96 Touch
real-time PCR detection system (Bio-Rad, CA, USA). To amplify
the vector, we used sequences annealing the human WAS described
by Charrier et al.45 and HIV-psi sequences (forward, 50-CAGGA
CTCGGCTTGCTGAAG-30, reverse, 50-TCCCCCGCTTAATACTG
ACG-30, and probe, 50-FAM-CGCACGGCAAGAGGCGAGG-TAM
RA-30). Titin was used as endogenous two-copy gene control (for-
ward, 50-AAAACGAGCAGTGACGTGAGC-30, reverse, 50-TTCAG
TCATGCTGCTAGCGC-30, and probe: 50-FAM-TGCACGGAAGC
GTCTCGTCTCAGTC-TAMRA-30). Serially diluted plasmid DNA
containing the relevant sequences was used as a standard curve,
with all measurements performed in duplicate.Proliferation and IL-2 Production of Murine T Cells
Murine T cells were purified from spleen with a CD90.2 MicroBeads
isolation kit (Miltenyi Biotec). For TCR stimulation, 96-well plates
were coated with 1 mg/mL anti-CD3e (functional grade purified)
(Affymetrix, eBioscience). CD90.2+ cells were preincubated with
CFSE (5-(and 6)-carboxyfluorescein diacetate, succinimidyl ester)
dye (CellTrace CFSE cell proliferation kit, Thermo Fisher Scientific)
and plated in triplicate for 5 days in RPMI 1640 supplemented with
10% FCS and 1% penicillin/streptomycin. At day 3, supernatant
from each well was saved for IL-2 analysis (DuoSet ELISA mouse
IL-2, R&D System, Minneapolis, MN, USA) following the manufac-
turer’s instructions. At day 5, proliferation was measured by flow
cytometry in a CyAn ADP analyzer (Beckman Coulter), and theMolecular Theanalysis was performed with FlowJo software (Tree Star, Ashland,
OR, USA).
Flow Cytometry Analysis
Murine cells from in vitro experiments and those harvested from en-
grafted mice were fixed with 4% formaldehyde, washed, and permea-
bilized with methanol (on ice) for 1 h. After that, the cells were resus-
pended in PBS+0.1% Triton X-100+3% BSA and blocked with
purified anti-mouse CD16/32 (10 mg/mL) (BioLegend) and 5%
normal goat serum. The cell suspension was stained intracellularly
with monoclonal antibody anti-human/mouse WASP (F8) (Santa
Cruz Biotechnology) and purified mouse IgG2a isotype control (Bio-
Legend) in PBS+0.1% Triton X-100+3% BSA buffer. After washing, a
secondary antibody goat anti-mouse IgG2a-FITC conjugate (ad-
sorbed against human Igs) (SouthernBiotech, Birmingham, AL,
USA) was used. The antibodies used for surface staining were as fol-
lows: Brilliant Violet 421 anti-mouse/human CD45R/B220, Brilliant
Violet 421 anti-mouse CD3, PE anti-mouse/human CD11b, Brilliant
Violet 421 anti-mouse Ly6G/Ly6C (Gr1) (all from BioLegend), and
APC mouse anti-mouse CD45.2 (BD Pharmingen). Samples were
analyzed using a FACS LSR II flow cytometer (Becton Dickinson,
NJ, USA) and the analysis software FlowJo.
For counting murine PLTs, blood was collected in tubes containing
20 mL of heparin andmeasured in the Sysmex XE-5000 automated he-
matology system (Sysmex, Japan).
Human primary cells were stained with anti-CD34-PE-Cy7, anti-
CD41a-PE, and CD42b-APC (all from eBioscience) and cells lines
with anti-CD41a-PE and CD42b-APC to evaluate megakaryocytic
differentiation. Cells were incubated during 30 min at 4C and
washed with PBS at 300  g for 5 min prior to acquisition. For intra-
cellular WASP determination, 105 cells were washed and fixed with
2% PFA during 20 min at RT. Permeabilization was performed
with 0.2% saponin (Sigma-Aldrich) in PBS+3% BSA (Sigma-Aldrich)
and blocking with FcR blocking reagent (Miltenyi Biotec) and 5% of
normal goat serum (Abcam). Cells were then incubated 1 h on ice
with anti-WASP (1:50, EP2541Y, Abcam) or rabbit IgG isotype con-
trol (Abcam). Secondary goat anti-rabbit IgG-FITC (AB6717, Ab-
cam) was added at 1:1,000 during 40 min on ice. Acquisition was per-
formed on a FACSCanto II (BD Biosciences) cytometer. Data were
analyzed with FlowJo (Tree Star) and FACSDiva (BD Biosciences)
software. Gates and analysis strategy for WASP and EGFP expression
are shown in Figures S1, S3, S4, and S5A. Briefly, WASP expression is
referred to as MeFI of the WASP+ population/MeFI of the isotype
control or WASKO population, and fold expression uses as a control
the expression of non-differentiated cells (CD41CD42 or CD34+,
depending on the model):
Expression =
WASP MeFI of WASP + cells in selected population
WASP MeFI of IsC in total selected population
Fold expression =
Expression in selected population
Expression in undifferentiated populationrapy: Methods & Clinical Development Vol. 19 December 2020 233
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Statistical comparisons were performed with GraphPad Prism soft-
ware (GraphPad, San Diego, CA, USA). A non-parametric test
(Mann-Whitney test), two-tailed p value (statistical significance was
defined as a p value <0.05), two-way ANOVA, Bonferroni Post-
Test, and an unpaired t test were used. All data are expressed as
mean ± SEM.
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